A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for StageIII-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC) III
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-689
- Sponsors Merck Sharp & Dohme
- 11 Sep 2019 This trial has been suspended in Spain, according to European Clinical Trials Database.
- 08 Jul 2019 Planned End Date changed from 21 Jan 2026 to 30 Jul 2026.
- 08 Jul 2019 Planned primary completion date changed from 21 Jan 2023 to 30 Jul 2025.